Logo

Symyx Closes Deal to Buy MDL from Elsevier for $123M

Oct 03, 2007
NEW YORK (GenomeWeb News) - Symyx Technologies said yesterday that it has closed its $123 million all-cash purchase of Elsevier’s MDL Information Systems business.
 
Symyx said the final purchase price will be subject to "working capital and other adjustments."
 
The company also has set up a $25 million back-up line of credit for working capital and for future growth initiatives.
 
Symyx struck the agreement to buy MDL in August. At the time, it said it expected combined software and database operations to be around $100 million in 2008. At the time of the agreement, Symyx said MDL had around 1,000 customers and around 50,000 content and software users.
 
Symyx said this week that it expects to incur “significant restructuring and one-time acquisition costs" in the fourth quarter of 2007.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.